920739-17-9

Upstream product

• 150026-75-8 (2-(2-(3-(3(R)-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-hydroxypropyl)phenyl)-2-propanol) 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 158966-92-8 montelukast 
• 866923-62-8 2-(1-((((R)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)sulfanyl)methyl)cyclopropyl)acetonitrile 
• 851755-58-3 montelukast tert-butylamine salt 
• 577953-88-9 1-(((1(R)-(3-(2-(7-chloro-2-quinolinil)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid dicyclohexylamine salt 
• 855473-51-7 1-(((1(R)-(3-(2(E)-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid methyl ester 

Relevant academic research and scientific papers

PREPARATION OF MONTELUKAST AND ITS SALTS

There is provided a process for the preparation of montelukast of the Formula (I).

PROCESS FOR PREPARING MONTELUKAST AND SALTS THEREOF USING OPTICALLY IMPURE 2-(2-(3(S)-(3-(7-CHLORO-2-QUINOLINYL)ETHENYL)PHENYL)-3-HYDROXYPROPYL)PHENYL-2-PROPANOL

A process for preparing montelukast and salts thereof using an optically impure 2-(2-(3(S)-(3-(7-chloro-2-quinolinyl)-ethenyl)-phenyl)-3-(hydroxylpropyl)phenyl)-2 propanol as starting material, which contains the (R)-enantiomer impurity in the range of greater than 0.5% to about 8.0% by weight, is disclosed. The process described herein using an optically impure material results in the final product, montelukast sodium, in optical purity of greater than 99.7% enantiomeric excess.